Document is current

Article History

Accepted: 10 February 2025

First Online: 13 March 2025

Declarations

:

: This research was funded by Shenzhen Salubris Pharmaceuticals Co., Ltd. The funder was involved in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication.

: The authors have no conflicts of interest regarding the content of this article. The study sponsor was involved in the study design and data collection, analysis, and interpretation.

: The study was registered with Chinadrugtrials.org, registration number CTR20202454, and was approved by the ethical committee of the Medical Science Research Ethics Committee, Peking University Third Hospital, China (D2020110). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: All participants gave written informed consent for participation in the study.

: Not applicable.

: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: Research design: Dongyang Liu and Haiyan Li. Writing—original draft, reviewing: Cheng Cui and Lei Geng. Methodology, data acquisition, and interpretation: Cheng Cui and Ruijie Zhang. Formal analysis and validation: Zichen Liu. Study execution: Xiaohong Wang and Xiaoye Niu. Supervising and resources: Wei Lin. All authors have read and approved the final manuscript.